Autopsy report · NCT04636073

The Leaflex™ Early Feasibility Study

“Reprioritization of attention and resources by Sponsor.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Pi-cardia

Sponsor type

Industry

Conditions

Aortic Valve Stenosis

Interventions

Leaflex™ Performer

Participants

0

Trials that died the same way

• An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
  “Sponsor resource allocation” (68% match in meaning)
• Effects of Dietary Supplements on Nail and Hair Health
  “Strategic change by sponsor” (64% match in meaning)
• Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
  “Strategic decision of Sponsor” (63% match in meaning)
• Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
  “Sponsor strategy” (63% match in meaning)
• Study on Safety and Performance of Medtentia Mitral Valve Repair System in Surgical Repair of Mitral Regurgitation
  “Strategic decision by Sponsor” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.